Investment Rating - The report maintains an "OUTPERFORM" rating for Luzhou Laojiao with a target price of RMB 205.00, while the current price is RMB 130.14 [2][8][14]. Core Insights - The report highlights three favorable factors for the Chinese stock market, including continuous policy dividends, accelerated return of international capital, and recovery of economic fundamentals, which have positively impacted the allocation of Baijiu stocks [3][10]. - Luzhou Laojiao has shown resilience during the industry adjustment period, with a focus on steady revenue growth and a significant increase in the share of mid- to high-end products [11][12]. - The company has achieved a compound annual growth rate (CAGR) of 18.3% in total revenue and 27.9% in net profit from 2015 to 2024, maintaining positive growth for ten consecutive years [12][13]. Financial Performance Summary - For the fiscal year 2024, the company reported revenue of RMB 31.196 billion and a net profit of RMB 13.473 billion, with expectations for continued growth in the following years [4][9]. - The gross profit margin has increased significantly, reaching 87.5% in 2024, benefiting from the higher proportion of mid- to high-end products [13]. - The company has committed to a dividend payout ratio of 65% for 2024, with plans to increase it to 70% and 75% in subsequent years, ensuring strong shareholder returns [14].

采浆规模稳步提升，静待新产能释放 派林生物(000403) ——派林生物 2024 年报点评 股票研究 /[Table_Date] 2025.05.04 2025-05-15 [Table_Industry] 医药/必需消费 [Table_Invest] 评级： 增持 [Table_Target] 目标价格： 27.86 [Table_CurPrice] 当前价格： 21.90 [Table_Market] 交易数据 总市值（百万元） 16,011 总股本/流通A 股（百万股） 731/727 流通 B 股/H 股（百万股） 0/0 本报告导读： 公司当前共有 36 个在营浆站，2024 年采浆量超 1400 吨，二期产能扩产完成后投浆 能力和产品工艺水平都将进一步提升，维持优于大市评级。 投资要点： | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 2,329 | 2,655 | 3,090 | 3,460 | 3,834 | ...

首次覆盖：专注于小分子肿瘤精准治疗，扭亏为盈迎来拐点 Focusing on Precision Therapy with Small Molecules in Oncology, Achieving Profitability and Reaching an Turning Point: Initiation [Table_yemei1] 观点聚焦 Investment Focus 研究报告 Research Report 14 May 2025 和誉-B Abbisko (2256 HK) [Table_Info] 首次覆盖优于大市 Initiate with OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$8.06 目标价 HK$13.40 HTI ESG 4.8-4.8-4.5 - -G: 0- , (Please refer to the Appendix for ESG comments) 市值 HK$5.48bn / US$0.70bn 日交易额 (3 个月均值) US$5.95mn 发行股票数目 680.11mn 自由流通股 (%) 67% 年股价最高最低值 HK$8. ...

14 May 2025 研究报告 Research Report 京东健康 JD Health International (6618 HK) 25Q1 业绩大幅超市场预期，建议关注后续大促季表现和即时零售布局展开 25Q1 beat, attention on upcoming promotional season and instant retail initiatives [Table_yemei 观点聚焦 1] Investment Focus 收入增长提速，同环比双增。25Q1 公司收入规模突破历史最好季 度表现，达到 166.5 亿元（YoY +25.5%，QoQ +0.8%），好于全年指 引（双位数增长，据 24 年公开业绩会）。据管理层，收入端提速 归因于，1）流感；2）"三高"原研药的增长；3）保健品的增长， 及品牌方广告投入的增加。 议价能力提升，规模效应下利润空间持续释放。25Q1 公司实现经 营利润 10.7 亿元（+119.8%），经营利润率 6.4%（+2.8pp），经营 利润率大幅提升带动净利润增长。公司实现经调整净利润 17.7 亿 元（+47.7%），对应净利率 10.6%（ ...

Investment Rating - The report does not explicitly state an investment rating for Samsonite, but it indicates a challenging environment for revenue and profit performance [1][9]. Core Insights - In 1Q25, Samsonite's net sales decreased by 4.5% year-on-year to $797 million, primarily due to weak demand in North America and China, along with a high base from the previous year [2][9]. - The company aims to maintain gross margin levels despite a 100 basis points decline to 59.4% in 1Q25, attributed to changes in geographic sales mix [2][9]. - Adjusted EBITDA fell by 20.9% year-on-year, leading to an adjusted EBITDA margin of 18.8%, down 280 basis points [2][9]. - Adjusted net income decreased by 40.3% year-on-year, driven by lower EBITDA, increased depreciation, net interest expenses, and a higher effective tax rate [2][9]. - The company reported a negative adjusted free cash flow of $41 million in 1Q25, reversing from a positive position due to EBITDA decline and increased net working capital [2][9]. Regional Performance - Sales in Asia and North America were weak, with Asia's revenue down 7% and North America's down 8% [3][10]. - Europe showed strong growth with a 4.4% increase in net sales, supported by positive growth across all core brands [3][10]. - Latin America’s sales remained flat, with a notable decline in Mexico offset by strong growth in Chile [3][10]. Channel Performance - The Direct-to-Consumer (DTC) channel accounted for 38.2% of revenue in 1Q25, with e-commerce contributing 10.6% and offline retail 27.5% [4][11]. - The offline retail business saw a decline of 2.6%, primarily due to reduced customer traffic, while wholesale business declined by 6.1% [4][11]. Tariff Policy and Mitigation Strategies - The U.S. tariff policy remains unclear, causing caution among consumers and wholesale customers [5][12]. - The company has reduced its sourcing from China to 14% and plans to further decrease this by year-end, employing various strategies to mitigate potential tariff impacts [5][12]. Future Guidance - Management expects 2Q25 net sales growth to be similar to 1Q25, with a mid-single-digit decline in net revenue on a constant currency basis [6][13]. - Long-term growth is anticipated to be supported by strong travel trends, despite short-term macroeconomic uncertainties affecting consumer demand [6][13].

Investment Rating - The investment rating for JD Logistics is maintained at "OUTPERFORM" [2][5]. Core Insights - JD Logistics reported Q1 2025 results with revenue of RMB 46.97 billion, reflecting a year-on-year growth of 11.5%, and a Non-IFRS net profit of RMB 0.751 billion, up 13.4% year-on-year [3][10]. - The company is expected to achieve total revenue of RMB 203.3 billion in 2025, representing an 11.2% increase, with a Non-IFRS net profit margin projected at 4.0% [5][11]. - The shift in valuation method from Price-to-Sales (PS) to Price-to-Earnings (PE) indicates the company's transition into a stable profitability phase [5][11]. Revenue and Profitability - For Q1 2025, JD Logistics' integrated supply chain customer revenue was RMB 23.2 billion, a 13.2% increase, driven by higher revenue from JD Group and a 13.1% increase in the number of integrated supply chain customers [3]. - The company's total revenue for Q1 2025 included RMB 32.27 billion from external customers, accounting for 69.4% of total revenue, with a 10.3% year-on-year growth [3][4]. - The gross profit margin for Q1 2025 was 7.2%, a decrease of 0.5 percentage points compared to the same period in 2024 [4]. Business Operations - JD Logistics has enhanced its express delivery capabilities through investments in air resources, land transport routes, and personnel, leading to significant growth in its express delivery business [4]. - The company launched its 10th dedicated freighter in January 2025, improving delivery efficiency and supporting growth in high-value services such as fresh produce delivery [4]. Financial Forecast - The forecast for JD Logistics includes a projected net profit of RMB 8.209 billion for 2025, with a target price set at HKD 19.79 based on a 15X PE valuation [5][11]. - The company aims to increase investments in 2025 to expand its customer base and enhance service quality [5].

Table_Title] 研究报告 Research Report 13 May 2025 乖宝宠物 Gambol Pet Group (301498 CH) 2024 年业绩亮眼，泰国布局与研发加码并进 24 Financial Year Performance Shines, Thailand Layout and R&D Increase in Tandem 寇媛媛 Yuanyuan Kou yy.kou@htisec.com [Table_yemei1] 热点速评 Flash Analysis Table_summary] Please see APPENDIX 1 for English summary 事件：2025 年 5 月 13 日，乖宝宠物食品集团股份有限公司（简称"公司"）举行 2024 年度业绩说明会。 公司业务营收利润增长亮眼，自有品牌为营收增长主引擎。公司 2024 年营业收入为 52.44 亿元，同比增长 21.22%； 24Q4 营业收入为 15.73 亿元。从产品角度考虑，主粮和零食业务是主要增长动力，其对应 2024 年营业收 入分别同比增长 28.88%和 14.66%。 ...

净利润增长提速，大客户驱动公司充分受益 数据港603881 ——2024 年及 2025 年一季度业绩点评 本报告导读： 净利润增速明显加快，大厂的核心数据中心服务商将充分受益。 投资要点： | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 1,542 | 1,721 | 1,806 | 1,968 | 2,007 | | (+/)% | 6.0% | 11.6% | 5.0% | 8.9% | 2.0% | | 净利润（归母） | 123 | 132 | 173 | 196 | 216 | | (+/)% | 4.6% | 7.5% | 30.6% | 13.5% | 10.0% | | 每股净收益（元） | 0.21 | 0.22 | 0.29 | 0.33 | 0.36 | | 净资产收益率(%) | 3.9% | 4.1% | 5.2% | 5.6% | 5.9% | | 市盈率现价&最新股本摊薄） | 163.18 | ...

[Table_subIndustry] 细分行业评级 医药制造业 增持 医药服务业 增持 本报告导读： 持续推荐创新药等投资主线 [Table_Industry] 医药 ——国泰海通医药 2025 年 5 月第一周周报 [Table_Invest] 评级： 增持 制药龙头恒瑞医药港股发行已通过港交所聆讯，有望持续催化创新药行情，持续推 进创新药等投资主线。 投资要点： 请务必阅读正文之后的免责条款部分 股 票 研 究 行 业 跟 踪 报 告 证 券 研 究 报 告 股票研究 /Table_Date] 2025.05.11 请务必阅读正文之后的免责条款部分 2 of 8 [table_Authors] 余文心分析师 郑琴分析师 谈嘉程分析师 02138676666 02138676666 02138676666 登记编号 S0880525040111 S0880525040108 S0880523070004 2025-05-12 [Table_Summary] 持续推荐创新药等投资主线。持续推荐景气度向上的创新药，维持 恒瑞医药、华东医药、翰森制药、贝达药业、信立泰、科伦药业、 百利天恒、荣昌生物、科伦博泰生 ...

2024 年报及 25Q1 季报点评 股票研究 /Table_Date] 2025.05.12 2025-05-13 首次覆盖：Q1 来水不佳，湖北现货即将转正 湖北能源000883 [Table_Industry] 电力/公用事业 [Table_Invest] 评级： 增持 [Table_Target] 目标价格： 5.61 [Table_CurPrice] 当前价格： 4.66 [Table_Market] 交易数据 总市值（百万元） 30,292 总股本流通A 股（百万股） 6,500/6,480 本报告导读： 请务必阅读正文之后的免责条款部分 公司 24 年和 25Q1 业绩分别受到减值和来水不佳影响，湖北现货市场推进，看好公 司电源长期价值释放。 投资要点： | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 18,669 | 20,031 | 20,045 | 21,655 | 21,980 | | (+/)% | 9 ...